Glenmark Pharma has reported a rise of 23.5% (YoY) in its first quarter net profit. In an interview with CNBC-TV18, Surajit Pal, pharma analyst, Elara Capital said, the top-line is very much in line, just 3% below his expectations. “Bottom-line margin has increased quite significantly, much above our expectation,” he added.
first published: Jul 26, 2011 03:24 pm
A collection of the most-viewed Moneycontrol videos.
